In CommitteeFiled May 19, 2026
Sponsor: Rep. Sorensen, Eric [D-IL-17] (D)
Latest Action
Referred to the House Committee on Energy and Commerce.
May 19, 2026
Summary
The bill amends the Federal Food, Drug, and Cosmetic Act so the FDA can deny petitions that are intended to delay the approval of new drug applications. It sets a 60‑day filing deadline, defines factors for judging intent, and requires referrals of abusive petitions to the FTC. The change aims to speed the entry of affordable medicines by curbing strategic delays.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Track this bill
Get real-time alerts when HR 8908 changes status, plus AI-powered summaries and stage predictions.
Sign up free